Advanced Biomedical Technologies Inc   (ABMT)
Other Ticker:  
Price: $0.0006 $0.00 0.000%
Day's High: $0.0006 Week Perf: -95 %
Day's Low: $ 0.00 30 Day Perf: -98.5 %
Volume (M): 0 52 Wk High: $ 0.09
Volume (M$): $ 0 52 Wk Avg: $0.04
Open: $0.00 52 Wk Low: $0.00

 Market Capitalization (Millions $) 0
 Shares Outstanding (Millions) 70
 Employees -
 Revenues (TTM) (Millions $) 0
 Net Income (TTM) (Millions $) -1
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Advanced Biomedical Technologies Inc
Advanced Biomedical Technologies Inc. is a company that specializes in the development of innovative medical technologies. These technologies focus on improving patient care, diagnosis, and treatment in various healthcare fields. The company's aim is to provide advanced solutions that enhance medical procedures and offer better outcomes for patients. Advanced Biomedical Technologies Inc. is committed to research and development, constantly working towards breakthrough innovations in the medical industry.

   Company Address: 200 Park Avenue New York City 10166 NY
   Company Phone Number: 766-7898   Stock Exchange / Ticker: ABMT


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Sep Acquisition Corp

SEPA Reports Decline in First Quarter 2024 Performance Among Many Companies

Sep Acquisition Corp, a prominent player in the Medical Equipment and Supplies sector, recently announced its financial results for the first quarter of 2024. The company reported an operating loss of $-1.210327 million, which has raised concerns among investors. Additionally, Sep Acquisition Corp experienced a net loss of $-3.044 million, a significant deviation from its previously balanced books in the same reporting period a year ago. These developments have resulted in a decline in Sep Acquisition Corp shares and pose questions about the company's future prospects.
1. Declining Shares and Trading Performance:
Sep Acquisition Corp shares have witnessed a significant decline, decreasing by a notable percentage compared to the previous year. This decline indicates a lack of investor confidence in the company's financial performance and future potential. Moreover, the company's shares currently trade only 9.8% above its 52-week low, suggesting a weak market sentiment.

Vivos Therapeutics Inc

Vivos Therapeutics Inc. Rises Above Challenges in First Quarter of 2024

Vivos Therapeutics Inc, a leading player in the field of sleep disorder treatments, has reported its financial results for the first quarter of 2024. While the company witnessed a decrease in losses per share and improvement in its earnings per share, its revenue took a hit, demonstrating a decline both year-on-year and sequentially. However, the recent announcement of Medicare's full approval for reimbursement of Vivos Therapeutics' flagship CARE Oral devices brings positive prospects for the company.
Financial Analysis:
During the first quarter of 2024 earnings season, Vivos Therapeutics Inc showed a decrease in losses per share, from $-1.75 to $-1.63, compared to the same period a year ago. Moreover, the company recorded an improvement in earnings per share, with figures showing growth from $-2.31 in the prior financial reporting period. These results indicate positive developments in the company's financial performance.

Haemonetics Corporation

Haemonetics Corporation: Strong Revenue Growth Fails to Boost Earnings in Recent Fiscal Report

Haemonetics Corporation, a leading Medical Equipment and Supplies company, recently announced its financial results for the most recent fiscal period. While the company experienced a double-digit increase in revenue, its net profit per share dropped significantly, leading to concerns about its financial performance.
In the most recent fiscal period, Haemonetics Corporation reported a 12.664% increase in revenue, reaching $343.91 million. This growth in revenue is noteworthy, especially when compared to the overall top-line growth of 7.27% experienced by the Medical Equipment and Supplies industry during the same period. This suggests that Haemonetics Corporation performed favorably compared to its industry peers.

Star Equity Holdings Inc

Headline: Star Equity Holdings Inc Faces Financial Decline in Q1 2024, Sparking Concern Among Investors

Headline: Star Equity Holdings Inc Faces Declining Earnings and Revenue in Q1 2024; Investors Express Concerns for Future Performance

Star Equity Holdings Inc, a leading Medical Equipment and Supplies company, has reported a significant decline in earnings and revenue for the first quarter of 2024. As the earnings season unfolds, investors are taking note of the company's financial performance, which reflects a setback compared to the previous year.
During the first quarter of 2024, Star Equity Holdings Inc experienced a substantial slip into a shortfall of $-0.14 per share, a significant decrease from $0.03 per share reported in the same period a year prior. Furthermore, earnings per share fell from $0.04 per share in the previous reporting season.

Prosomnus Inc

Prosomnus Inc's Impressive Financial Performance Sets Industry Standard in First Quarter of 2024

Prosomnus Inc, a medical equipment and supplies company, has reported a positive first quarter for 2024, with a decrease in loss per share compared to the previous year. The company's earnings per share improved from -$0.42 to -$0.02, indicating a positive trend in profitability.
Furthermore, Prosomnus Inc witnessed a significant increase in revenue, with a jump of 47.632% to $7.46 million compared to $5.05 million in the same reporting season a year before. However, there was a sequential decline in revenue of -20.199% from $9.35 million.
These positive financial results place Prosomnus Inc ahead of its peers in the Medical Equipment and Supplies sector, as it outperformed the overall sector's 7.27% revenue growth during the same period.


Advanced Biomedical Technologies Inc's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com